VRTX
VERTEX PHARMACEUTICALS INC / MANasdaqResearch view
Healthcare · Pharmaceutical Preparations · Large-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$130.4B
Enterprise Value$125.5B
Income$4.0B
Sales$12.0B
Book/sh$73.64
Cash/sh$20.07
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio2.46
Current Ratio2.90
Debt/Eq0.01
EPS (ttm)$15.32
EPS this Y836.5%
EPS past 3/5Y6.1%
Sales past 3/5Y10.4%
EPS Y/Y TTM836.5%
Sales Y/Y TTM8.9%
Shs Outstand253.46M
ROA15.4%
ROE21.2%
ROIC26.0%
Gross Margin—
Oper. Margin34.8%
Profit Margin32.9%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$7.6B
2021
$8.9B
2022
$9.9B
2023
$11.0B
2024
$12.0B
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $2.8B | $4.3B | $3.8B | $-232.9M | $4.2B |
| Net Income | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B |
| Diluted EPS | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 |
| Operating Cash Flow | $2.6B | $4.1B | $3.5B | $-492.6M | $3.6B |
| Free Cash Flow | $2.4B | $3.9B | $3.3B | $-790.3M | $3.2B |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Capital-light: capex is $437.6M against $3.6B operating cash
COMMUNITY · $VRTX0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Pharmaceutical Preparations
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.